Company intelligence / Profile preview

CONTERA Management

Ownership: Private
Development stage: Other

Overview

Contera Pharma develops therapies for neurological disorders using both antisense oligonucleotides and small molecules. Its lead program JM‑010 reached Phase 2 trials for drug-induced dyskinesia in Parkinson’s disease but recently faced a clinical setback. Other programs target rare CNS diseases such as leukodystrophies and movement disorders. The company emphasizes precision medicine approaches to address unmet needs in neurology.

Recent news indicates that Bukwang Pharmaceutical halted JM‑010 clinical trials after a setback as of May 2024.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotideSmall moleculeDrug delivery device
Industry: Biotech

Partnerships

Bukwang PharmaceuticalMedici Investment

Beyond the preview

Go deeper on CONTERA Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CONTERA Management.

Explore the full profile